On May 27, WuXi XDC (02268.HK) declined 3.04% in regular trading to 55.75 HKD/share, with turnover of approximately 86.31 million HKD, as intensive buyback plans from both the company and its parent failed to stem ongoing sector weakness.

On the news front, WuXi XDC previously announced a share repurchase plan of up to 100 million USD using internal funds, while parent company WuXi Biologics further disclosed a buyback plan of up to 400 million USD on May 26, bringing the combined group repurchase scale to 500 million USD. Despite the significant capital commitment signaling management confidence in intrinsic value, the measures have not effectively reversed downward price momentum amid broad-based selling across the Life Sciences Tools and Services sector.

Within the sector, WuXi Biologics fell 1.34%, WuXi AppTec dropped 1.55%, and XtalPi declined 2.99%, while GenScript Biotech rose 3.69%. Guotai Junan Securities maintained an Overweight rating on WuXi XDC with a target price of 84.38 HKD, citing strong ADC pipeline growth prospects and backlog orders of approximately 14.89 billion USD as of end-2025, representing 50.3% year-over-year growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)